semaglutide off shortage list taken On February 21, 2025, the FDA announced that semaglutide, the active Compounded GLP-1 Medications: What’s Changing

The progressive form, MASH, exhibits hepatocyte damage, inflammatory cell infiltration, and variable degrees of tissue fibrosis, with advanced fibrosis representing the predominant prognostic determinant for hepatic morbidity and mortality, as well as an additional risk factor for extrahepatic complications

Ile 17 MAR709 experiments have tested the concurrent substitution of Gln 17 , Ala 18 , and Ala 19 from GLP-1 to Ile 17 , His 18 , and Gln 19 from GIP, and found that GLP-1 activity decreased (EC 50 : 0.022 nM0.140 nM) while that of GIP scarcely increased (EC 50 : 6.258 nM5.530 nM)

GLP-1 Receptor Agonists (Critical FY2024+ Coding) GLP-1 receptor agonists mimic the incretin hormone glucagon-like peptide-1, suppressing appetite centrally and slowing gastric emptying

doi: 10.1038/nrgastro.2017.75 41 GibsonG